Corvus registers Phase 1b trial of soquelitinib in hidradenitis suppurativa

Corvus Pharmaceuticals had one trial registry update during the week, covering a new study of its oral drug soquelitinib.

• Corvus Pharmaceuticals is sponsoring a Phase 1b, open-label study evaluating the safety and efficacy of oral soquelitinib in adults with moderate-to-severe hidradenitis suppurativa, registered September 18, 2026, and recruiting, with an estimated enrollment of 25 participants.¹ The study's primary purpose is treatment, and participants receive active tablets orally twice daily for 84 days.¹ Primary completion is estimated for December 2027. The primary outcome is the incidence, nature, and severity of treatment-emergent adverse events of soquelitinib, including changes in laboratory values, vital signs, and ECGs.¹ Secondary outcomes include the percentage of participants achieving HiSCR50, HiSCR75, and HiSCR90 at Week 12, along with changes in the Hidradenitis Suppurativa Severity Score System (IHS4), lesion count, HS-Skin Pain NRS, HiSQoL, and DLQI.¹ The trial is running at 11 sites in the United States, including locations in Kentucky, New York, Ohio, Pennsylvania, and other states, with several sites listed as not yet recruiting.¹